GSK plc

Finding Value Opportunities Among Highly Rated Stocks

U.S. equity markets moved lower this week, with broad weakness across most major ETFs and sector benchmarks.

INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?

Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.

GSK Presents Jideytro Data for Potential Use in First-Line NSCLC

GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.

GSK Gets a Lung Cancer Payoff

Shares rose after strong clinical data strengthened the case for its $10.6 billion Nuvalent acquisition and broader push to rebuild oncology around lung cancer.

Big Pharma Is Pouring Billions Into China’s Biotechs

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows

94% objective response rate at 15.2 months follow-up90% of patients were progression free at 12 months, with median PFS rate still to be reached70% of patients with measurable brain metastases achieve…

GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff

GSK (NYSE:GSK) is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through …

GSK Says Plans To Stop Manufacturing At Co's Dresden, Germany Flu Vaccine Manufacturing Site In Summer 2027

- Reuters 

GSK’s mRNA Flu Vaccine Shows Promise, But Can It Deliver Late-Stage?

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid-stage results in both younger and older adults. The mRNA-based candidate g…

GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff

GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.

GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript

GHO Capital appoints Vivid Sehgal as Operating Partner

Vivid brings over 30 years of operational and financial leadership in healthcare and life sciences, being a founder of LivaNova PLC, led OPEN Health as Interim Group CEO, and held senior roles at Glax…